CA3026414A1 - Compositions and methods for treating inflammatory bowel diseases (ibds) and other disorders - Google Patents

Compositions and methods for treating inflammatory bowel diseases (ibds) and other disorders Download PDF

Info

Publication number
CA3026414A1
CA3026414A1 CA3026414A CA3026414A CA3026414A1 CA 3026414 A1 CA3026414 A1 CA 3026414A1 CA 3026414 A CA3026414 A CA 3026414A CA 3026414 A CA3026414 A CA 3026414A CA 3026414 A1 CA3026414 A1 CA 3026414A1
Authority
CA
Canada
Prior art keywords
pharmaceutical composition
fecal
species
group
fold
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
CA3026414A
Other languages
English (en)
French (fr)
Inventor
Thomas J. Borody
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Finch Therapeutics Holdings LLC
Original Assignee
Crestovo Holdings LLC
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Crestovo Holdings LLC filed Critical Crestovo Holdings LLC
Publication of CA3026414A1 publication Critical patent/CA3026414A1/en
Abandoned legal-status Critical Current

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/66Microorganisms or materials therefrom
    • A61K35/74Bacteria
    • A61K35/741Probiotics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/185Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19Carboxylic acids, e.g. valproic acid
    • A61K31/195Carboxylic acids, e.g. valproic acid having an amino group
    • A61K31/197Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid or pantothenic acid
    • A61K31/198Alpha-amino acids, e.g. alanine or edetic acid [EDTA]
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A61K31/525Isoalloxazines, e.g. riboflavins, vitamin B2
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/70Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7028Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/70Carbohydrates; Sugars; Derivatives thereof
    • A61K31/715Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
    • A61K31/732Pectin
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/37Digestive system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/66Microorganisms or materials therefrom
    • A61K35/74Bacteria
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00Medicinal preparations containing peptides
    • A61K38/04Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/06Tripeptides
    • A61K38/063Glutathione
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/0012Galenical forms characterised by the site of application
    • A61K9/0031Rectum, anus
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/0012Galenical forms characterised by the site of application
    • A61K9/0053Mouth and digestive tract, i.e. intraoral and peroral administration
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00Drugs for disorders of the alimentary tract or the digestive system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K2035/11Medicinal preparations comprising living procariotic cells
    • YGENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02ATECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Molecular Biology (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nutrition Science (AREA)
  • Physiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Inorganic Chemistry (AREA)
  • Biochemistry (AREA)
  • Developmental Biology & Embryology (AREA)
  • Virology (AREA)
  • Zoology (AREA)
  • Biotechnology (AREA)
  • Biomedical Technology (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Cell Biology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines Containing Plant Substances (AREA)
  • Polysaccharides And Polysaccharide Derivatives (AREA)
  • Saccharide Compounds (AREA)
  • Medicinal Preparation (AREA)
CA3026414A 2016-06-01 2017-06-01 Compositions and methods for treating inflammatory bowel diseases (ibds) and other disorders Abandoned CA3026414A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201662344053P 2016-06-01 2016-06-01
US62/344,053 2016-06-01
PCT/US2017/035449 WO2017210428A1 (en) 2016-06-01 2017-06-01 Compositions and methods for treating inflammatory bowel diseases (ibds) and other disorders

Publications (1)

Publication Number Publication Date
CA3026414A1 true CA3026414A1 (en) 2017-12-07

Family

ID=60479147

Family Applications (1)

Application Number Title Priority Date Filing Date
CA3026414A Abandoned CA3026414A1 (en) 2016-06-01 2017-06-01 Compositions and methods for treating inflammatory bowel diseases (ibds) and other disorders

Country Status (7)

Country Link
US (2) US20170348360A1 (https=)
EP (1) EP3462882A4 (https=)
JP (1) JP2019520340A (https=)
CN (1) CN109803534A (https=)
AU (1) AU2017274416C1 (https=)
CA (1) CA3026414A1 (https=)
WO (1) WO2017210428A1 (https=)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP4188110A4 (en) * 2020-07-30 2024-08-14 Bactana Corp. METHODS AND COMPOSITIONS FOR THE TREATMENT OF METABOLIC DISEASES

Families Citing this family (46)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2016268158B2 (en) 2015-05-22 2022-03-17 Arizona Board Of Regents On Behalf Of Arizona State University Methods for treating autism spectrum disorder and associated symptoms
US20170360848A1 (en) 2016-06-15 2017-12-21 Arizona Board Of Regents On Behalf Of Arizona State University Methods for treating autism spectrum disorder and associated symptoms
US11213549B2 (en) 2016-10-11 2022-01-04 Finch Therapeutics Holdings Llc Compositions and method for treating primary sclerosing cholangitis and related disorders
WO2018071537A1 (en) 2016-10-11 2018-04-19 Crestovo Holdings Llc Compositions and methods for treating multiple sclerosis and related disorders
CA3211208A1 (en) 2017-04-03 2018-10-11 Gusto Global, Llc Rational design of microbial-based biotherapeutics
WO2018187464A1 (en) 2017-04-05 2018-10-11 Crestovo Holdings Llc Compositions and methods for treating diverticulitis and related disorders
CN110831606A (zh) 2017-04-05 2020-02-21 克雷斯顿沃控股公司 治疗帕金森氏病(pd)和相关疾病的组合物和方法
JP2020521760A (ja) 2017-05-26 2020-07-27 クレストヴォ・ホールディングス・エルエルシー 糞便微生物ベースの治療剤を含む凍結乾燥組成物ならびにそれを製造および使用する方法
MY201921A (en) * 2017-06-16 2024-03-23 Biofermin Pharmaceutical Co Ltd Agent for preventing or treating fat-associated diseases and/or inflammation
WO2018236979A1 (en) * 2017-06-20 2018-12-27 Cornell University Probiotic compositions and methods
WO2019032573A1 (en) 2017-08-07 2019-02-14 Finch Therapeutics, Inc. COMPOSITIONS AND METHODS FOR MAINTAINING AND RESTORING A HEALTHY INTESTINAL BARRIER
JP7460531B2 (ja) 2017-12-05 2024-04-02 バイオピーエルエックス,インコーポレイティド 微生物感染を防ぐための方法および組成物
EP3725321A4 (en) * 2017-12-12 2021-09-08 Morinaga Milk Industry Co., Ltd. COMPOSITION WITH A BACTERIUM OF THE GENUS BIFIDOBACTERIUM AS THE ACTIVE SUBSTANCE
GB2585291B (en) * 2018-02-02 2023-07-19 Univ Hong Kong Chinese Fecal fungome and therapeutic efficacy of fecal microbiota transplantation
WO2019157566A1 (en) * 2018-02-16 2019-08-22 St Vincent's Hospital (Melbourne) Limited Compositions and methods for promoting gut health
AU2019253616A1 (en) * 2018-04-13 2020-11-05 Med-Life Discoveries Lp Long chain dicarboxylic fatty acid (LCDFA) producing microbes and uses thereof
CN110396538B (zh) * 2018-04-24 2023-05-23 深圳华大生命科学研究院 偏头痛生物标志物及其用途
US11166990B2 (en) 2018-07-13 2021-11-09 Finch Therapeutics Holdings Llc Methods and compositions for treating ulcerative colitis
EP3870691A4 (en) * 2018-09-13 2022-09-07 Xbiome Inc. METHODS AND COMPOSITIONS FOR TREATING GASTROINTESTINAL AND INFLAMMATORY DISORDERS
US11911419B2 (en) 2018-09-27 2024-02-27 Finch Therapeutics Holdings Llc Compositions and methods for treating epilepsy and related disorders
WO2020227420A1 (en) * 2019-05-06 2020-11-12 The General Hospital Corporation Monitoring and altering the gut microbiome in disease
CN114364388A (zh) * 2019-07-11 2022-04-15 安东尼·米利斯 一种增强微生物植入的肠黏膜制备方法
US12290538B2 (en) 2019-07-19 2025-05-06 Finch Therapeutics Holdings Llc Methods and products for treatment of gastrointestinal disorders
CN110541026A (zh) * 2019-08-17 2019-12-06 昆明医科大学第一附属医院 一种检测溃疡性结肠炎的生物标志物及应用
AU2020365134A1 (en) * 2019-10-18 2022-06-02 Thaena Inc. Fecal-derived sterile postbiotic composition and method therefor
EP3839072A1 (en) * 2019-12-17 2021-06-23 Luxia Scientific Bacterial combinations predictive of the activity of multiple sclerosis
EP3838276A1 (en) * 2019-12-17 2021-06-23 Exeliom Biosciences Association of faecalibacterium prausnitzii strain cncm i-4573 with pentasa® for the treatment and prevention of gastrointestinal inflammation
US20220408780A1 (en) * 2020-02-11 2022-12-29 The E. Wolfson Medical Center A method effective for treating ulcerative colitis
US20230087012A1 (en) * 2020-02-14 2023-03-23 Cornell University Transferable microbiota for the treatment of ulcerative colitis
CN111304120B (zh) * 2020-02-24 2021-07-23 浙江大学 Blautia sp B2132菌在预防和/或治疗炎症性肠病中的应用
EP3875098A1 (en) * 2020-03-04 2021-09-08 Institut National De Recherche Pour L'agriculture, L'alimentation Et L'environnement Use of coprococcus bacteria for the treatment of metabolic syndrome and inflammatory bowel diseases
US11744866B2 (en) 2020-03-18 2023-09-05 Sabine Hazan Methods of preventing and treating COVID-19 infection with probiotics
CN115697084A (zh) * 2020-04-01 2023-02-03 沃尔夫森医疗中心 溃疡性结肠炎膳食、配方、产品及其方法
US20230256033A1 (en) * 2020-06-09 2023-08-17 Flagship Pioneering Innovations Vi, Llc Physiologically acceptable compositions containing microorganisms or microbial products
KR102169795B1 (ko) * 2020-06-24 2020-10-27 주식회사 엔테로바이옴 신규한 피칼리박테리움 프로스니치 eb-fpdk9 균주 및 그의 용도
KR102169794B1 (ko) * 2020-06-24 2020-10-27 주식회사 엔테로바이옴 신규한 피칼리박테리움 프로스니치 균주 eb-fpdk11 및 그의 용도
CN111888381A (zh) * 2020-09-18 2020-11-06 广西细微生物科技有限责任公司 一种肠道微生物移植工艺
KR102700146B1 (ko) * 2020-09-28 2024-08-28 씨제이바이오사이언스 주식회사 미생물을 포함하는 염증성 질환 진단 또는 치료용 조성물
US20220326255A1 (en) * 2021-04-01 2022-10-13 Medibeacon Inc. Methods of monitoring mucosal healing
EP4082545A1 (en) * 2021-04-27 2022-11-02 Diotheris Combination product and methods for preventing the emergence of antibiotic-resistant bacteria under antibiotic treatment
KR102337993B1 (ko) * 2021-10-27 2021-12-14 주식회사 바이오뱅크힐링 클로스트리디움 렙텀 균주, 및 그의 유래의 소포체 및 그의 항염증 및 항균 용도
CN113974159B (zh) * 2021-11-02 2023-06-27 美益添生物医药(武汉)有限公司 齿叶乳香树树脂在制备促进肠道有益菌增殖的产品中的应用
TW202400235A (zh) * 2022-05-13 2024-01-01 國立大學法人東京大學 治療或診斷炎症性腸疾病(ibd)之方法及組合物
CN115944655A (zh) * 2023-02-14 2023-04-11 上海奇诺普森生物科技有限责任公司 一种肠菌组合物及其在防治自闭症中的应用
CN119970806B (zh) * 2025-02-25 2026-03-03 浙江大学 多毛假解黄酮菌在制备预防、治疗和/或改善溃疡性结肠炎的药物中的应用
CN119709558B (zh) * 2025-02-26 2025-05-30 昆明医科大学第一附属医院(云南省皮肤病医院) 布劳特氏菌emf75-02b1b及其用途

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1510821A1 (en) * 2003-08-27 2005-03-02 Universiteit Utrecht Holding B.V. Diagnosis and treatment of mycobacterial infections
PH12013500224A1 (en) * 2010-08-04 2013-04-08 Borody Thomas J Compositions for fecal floral transplantation and methods for making and using them and devices for delivering them
MX2013010343A (es) * 2011-03-09 2014-04-30 Univ Minnesota Composicion y metodos para el transplante de microbiota de colon.
ES2662793T3 (es) * 2011-09-14 2018-04-09 Nubiyota Llc Complementos de medio y métodos para cultivar microorganismos anaerobios gastrointestinales humanos
EP2914135A1 (en) * 2012-11-01 2015-09-09 Rijksuniversiteit Groningen Methods and compositions for stimulating beneficial bacteria in the gastrointestinal tract
CA2899925A1 (en) * 2013-02-04 2014-08-07 Seres Therapeutics, Inc. Compositions and methods for inhibition of pathogenic bacterial growth
CN105228635A (zh) * 2013-03-05 2016-01-06 格罗宁根大学 Faecalibacterium prausnitzii HTF-F(DSM 26943)在抑制炎症中的应用
US20150246081A1 (en) * 2014-03-03 2015-09-03 Shayne Kenneth Morris Probiotics with methods for growth and use separately and in combination
US9783858B2 (en) * 2014-04-02 2017-10-10 Northwestern University Altered microbiome of chronic pelvic pain
MA41020A (fr) * 2014-11-25 2017-10-03 Evelo Biosciences Inc Compositions probiotiques et prébiotiques, et leurs procédés d'utilisation pour la modulation du microbiome

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP4188110A4 (en) * 2020-07-30 2024-08-14 Bactana Corp. METHODS AND COMPOSITIONS FOR THE TREATMENT OF METABOLIC DISEASES

Also Published As

Publication number Publication date
JP2019520340A (ja) 2019-07-18
WO2017210428A1 (en) 2017-12-07
US20210106629A1 (en) 2021-04-15
US20170348360A1 (en) 2017-12-07
EP3462882A4 (en) 2020-01-22
AU2017274416C1 (en) 2022-07-07
EP3462882A1 (en) 2019-04-10
CN109803534A (zh) 2019-05-24
AU2017274416B2 (en) 2022-01-27
AU2017274416A1 (en) 2019-01-03

Similar Documents

Publication Publication Date Title
US20210106629A1 (en) Compositions and Methods for Treating Inflammatory Bowel Diseases (IBDs) and Other Disorders
JP7737219B2 (ja) 潰瘍性大腸炎を治療するための方法
US11357801B2 (en) Methods for treating autism spectrum disorder and associated symptoms
CN114366759A (zh) 用于治疗自闭症谱系障碍及相关症状的方法
CA3003138A1 (en) Compositions and methods for fecal microbiota-related therapy
CA3154308A1 (en) Compositions and methods for treating autism spectrum disorder
WO2018071534A1 (en) Compositions and methods for treating irritable bowel syndrome and related disorders
WO2019075344A1 (en) FECAL MICROBIOTE TRANSPLANTATION TO TREAT HEMORRHAGIC RECTOCOLITE
US20210260136A1 (en) Compositions and Methods for Treating Multiple Sclerosis and Related Disorders
US20240173360A1 (en) Compositions and methods for treating epilepsy and related disorders
US20180099011A1 (en) Compositions and Methods for Treating Irritable Bowel Syndrome and Related Disorders
US20200188449A1 (en) Compositions and Methods for Treating Chronic Fatigue Syndrome and Related Disorders
WO2021097288A1 (en) Compositions and methods for treating neurodegenerative diseases
US10092601B2 (en) Compositions and methods for treating multiple sclerosis and related disorders
WO2021142358A1 (en) Compositions and methods for treating hepatic encephalopathy (he)
US20180099013A1 (en) Compositions and Methods for Treating Chronic Fatigue Syndrome and Related Disorders
US11040073B2 (en) Compositions and methods for treating diverticulitis and related disorders
HK40073622A (en) Methods for treating autism spectrum disorder and associated symptoms

Legal Events

Date Code Title Description
FZDE Discontinued

Effective date: 20230829